Compare iShares MSCI China ETF (MCHI) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs McKesson Corporation — how do they compare? iShares MSCI China ETF trades at $52.8 (market cap $5.94B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 18.3× iShares MSCI China ETF's market cap, and McKesson Corporation pays a 0.4% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and McKesson Corporation for 74 Days on average.
| MCHI | MCK | |
|---|---|---|
Market Cap | $5.94B | $108.46B |
Volume | 1,575,471 | 712,607 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $995.69 |
52-Week Low | $50.48 | $725.17 |
Typical Hold Time | 63 Days | 74 Days |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $51.64, down 1.11% with a bearish technical outlook. The ETF faces pressure from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with strong corporate profit growth but concerns about export controls and trade tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure while oscillators remain neutral.
The outlook remains cautious given China's macroeconomic headwinds and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations compared to US indices, but risks include potential export restrictions, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
